• Vaxil Locations
  • Contact Us
  • Subscribe
Vaxil Bio
  • About Vaxil
  • TEAM
  • INTELLECTUAL PROPERTY
  • News and Updates
  • In the Media

Q2 2019 FINANCIALS NOW AVAILABLE

Posted on June 30, 2019April 30, 2020 by David Goren
30 Jun

Q2 2019 financials now available under “Public Filings” section of the Vaxil website.

 

Attached:

FINANCIAL STATEMENTS (JUNE 30)

MANAGEMENT DISCUSSION AND ANALYSIS (JUNE 30)

This entry was posted in Annnouncements. Bookmark the permalink.
Vaxil Granted Significant US Patent For Anti-Infective Vaccines
Vaxil Bio Licenses P-Esbp for Targeted Cancer Therapy from BGN Technologies, the Technology Transfer Company of Ben-Gurion University, Israel

Vaxil Canada
First Canadian Place, 34th Floor, 100 King Street W., Toronto, Ontario. M2N 6N4 Canada

Vaxil Israel
3 Pinhas Sapir Street, 3rd Floor, Weizmann Science Park, 74140, Rehovot, Israel

Corporate

  • Home
  • About Vaxil
  • Vaxil Locations
  • Contact Us
  • Board & Executives
  • News and Updates

INVESTORS

  • Investor Presentations
  • Public Filings
  • News and Updates
  • In the Media
  • Video
  • Scientific Publications
Copyright 2023 © VAXIL BIO THERAPEUTICS | Vaxil Bio therapeutics is an Israeli biotech focused on cancer immunotherapy, based in the Weizmann Science Park in Rehovot, Israel. Vaxil is listed on the TSX-Venture as VXL
  • About Vaxil
  • TEAM
  • INTELLECTUAL PROPERTY
  • News and Updates
  • In the Media
  • Vaxil Locations
  • Contact Us
  • Subscribe